Meeting
2017 Gastrointestinal Cancers Symposium
A pilot study of apatinib reversing paclitaxel resistance in heavily pretreated advanced gastric cancer (AGC).
Authors
Rongbo Lin
Fujian Provincial Cancer Hospital, Fuzhou, China
Rongbo Lin , Shen Zhao , Hui Li , Jie Liu , Nanfeng Fan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Translational Research
Clinical Trial Registration Number
NCT02697838
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 89)
DOI
10.1200/JCO.2017.35.4_suppl.89
Abstract #
89
Poster Bd #
H1
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Interim safety analysis of a phase III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: The AIO-sto-0210 FLOT4 study.
First Author: Claudia Pauligk
Poster
2015 ASCO Annual Meeting
Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO.
First Author: Claudia Pauligk
Poster
2012 ASCO Annual Meeting
Tolerability and efficacy of a biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin regimen (TFOX) in previously advanced metastatic gastric and oesogastric junction (AGC) adenocarcinoma.
First Author: Simon Pernot
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
First Author: Izuma Nakayama